Financial Data and Key Metrics Changes - Total revenue for the second quarter was $8.3 million, up 18.3% year-over-year, marking the seasonally strongest quarter due to holidays [15] - Advertising revenue increased by 18.3% for the quarter, driven by strong growth in the Zedge Marketplace, despite lower ad revenue at Emojipedia [16] - GAAP loss from operations was $2.9 million, compared to a loss of $2.2 million last year, with a non-cash impairment charge of $3.7 million related to Emojipedia [21] - Non-GAAP net income was $0.8 million, with an EPS of $0.06, compared to a loss of $0.2 million and a loss per share of $0.01 last year [21] - Cash strengthened to $19.1 million with zero debt, and free cash flow yield remains in the double digits [13][22] Business Line Data and Key Metrics Changes - Zedge Marketplace revenue was up over 21% year-over-year, driven by strong advertising CPMs and subscription revenue [15] - Zedge Plus subscription revenue increased by 33% year-over-year, with the net active subscriber base growing by 49% to nearly 1.2 million subscribers [17] - Deferred revenue reached $6 million, up 5% sequentially and 39% year-over-year, reflecting future revenue with a 100% gross margin [17] - Zedge Premium GTV was up 15.7% from the year-ago quarter, and ARPM increased by 47.6%, indicating improved monetization efficiency [18] Market Data and Key Metrics Changes - The company is experiencing MAU contraction but is focused on acquiring higher-value users and monetizing the audience more effectively [5] - The operational focus includes building a high-quality outbound pipeline and better qualifying inbound requests [9] Company Strategy and Development Direction - The company aims to strengthen monetization in the marketplace, build DataSeeds deliberately, and expand the innovation pipeline in a disciplined manner [14] - Investments in optimizing ad inventory and subscription offerings are yielding positive results, with a focus on innovation in AI training data through DataSeeds.AI [5][7] - The company is exploring multimodal data, including images, audio, and video, to enhance its offerings [30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential of DataSeeds.AI and the ongoing interest from enterprise customers [8] - The company is cautious about scaling operations to avoid impacting profitability while building infrastructure and operational rigor [10] - Management acknowledged structural headwinds affecting Emojipedia and the need to adapt to changes in the search landscape [12] Other Important Information - The company has launched two more alpha products, bringing the total to four out of six planned for the fiscal year [11] - The cost of revenue was 6.8% of revenue, up from 6.4% last year due to increased production costs [19] - SG&A expenses decreased by about 6% to $6.7 million for the quarter, reflecting net savings from restructuring [20] Q&A Session Summary Question: Insights on DataSeeds and pipeline delivery - Management indicated that the progression of deals in DataSeeds.AI depends on successful proof of concepts and customer needs, with attractive margins thus far [26][28] Question: Updates on alpha product launches - Management shared that the new products are built on an evolving foundation for modular development, allowing for faster market entry [31][32] Question: Subscription revenue trends - The ongoing investment in optimizing subscription offerings is driving growth, with a focus on attracting prospective subscribers [34] Question: Zedge Marketplace performance - The strong performance is attributed to the overlap with year-end advertising spend and enhanced data science efforts for user segmentation [36][38] Question: Strategy for increasing active users - The company is employing new marketing strategies, testing product features, and utilizing data science to attract new users [40] Question: Progress on Tapedeck and music catalog - Management emphasized the importance of building a substantial and diverse music catalog to attract users, with ongoing efforts to promote the app [42][44]

Financial Data and Key Metrics Changes - The company ended 2025 with cash equivalents and investments of $656.6 million, a significant increase from $198.2 million at the end of 2024 [11] - R&D expenses for 2025 were $132 million, down from $168.6 million in 2024, primarily due to a reduction in preclinical and clinical costs [12] - G&A expenses increased to $38.6 million in 2025 from $23.8 million in 2024, driven by higher compensation and professional fees [13] - The net loss for 2025 was $154.7 million, an improvement from $177.8 million in 2024 [15] Business Line Data and Key Metrics Changes - The NDA for lorundrostat was accepted by the FDA, with a PDUFA target action date set for December 22, 2026, following five positive clinical trials demonstrating its efficacy [4][5] - The company is focusing on market access planning and payer engagement to ensure the value proposition of lorundrostat is understood [6] Market Data and Key Metrics Changes - Uncontrolled and resistant hypertension affects over 20 million people in the U.S., representing a significant market opportunity for lorundrostat [6] - The company is targeting the third line or later treatment space for lorundrostat, which aligns with the needs of resistant hypertension patients [19] Company Strategy and Development Direction - The company aims to position lorundrostat as a best-in-class therapy for uncontrolled or resistant hypertension, with ongoing evaluations for further clinical development in comorbidities [9] - The strategy includes expanding medical communications and increasing peer-reviewed publications to support the launch of lorundrostat [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the market opportunity for lorundrostat, especially with the upcoming competitive launch by AstraZeneca [18] - The company remains optimistic about payer access and the value proposition of lorundrostat in the resistant hypertension space [19] Other Important Information - The company is exploring additional indications for lorundrostat, particularly in conditions driven by dysregulated aldosterone, such as chronic kidney disease and obstructive sleep apnea [64] - The company is preparing for potential partnerships to maximize the value of lorundrostat, focusing on co-development opportunities [92] Q&A Session Summary Question: What insights are expected from the competitor's launch? - Management is keen to learn about pricing strategies and market positioning from the competitor's launch, emphasizing the large market opportunity for lorundrostat [18] Question: How confident is the company in payer interactions? - Management is optimistic about access, particularly for third-line treatment, and believes the comprehensive dataset will support favorable payer discussions [19] Question: What are the implications of the phase 2 OSA study results? - Management acknowledged the study's limitations but emphasized the importance of demonstrating robust blood pressure reduction in high-risk patients [26][28] Question: What is the commercial capability being built? - The company is expanding its commercial team and medical affairs capabilities to ensure a rapid uptake of lorundrostat upon approval [36] Question: How does the company view potential partnerships? - Management seeks partners that recognize the value of lorundrostat and are willing to engage in co-development opportunities [92]

Financial Data and Key Metrics Changes - Research and development (R&D) expenses in Q4 2025 totaled $9.9 million, up from $6 million in Q4 2024, with full-year R&D expenses reaching $33.7 million compared to $19.4 million in 2024, primarily due to higher clinical trial and manufacturing costs for soquelitinib and increased personnel costs [4] - Net loss for Q4 2025 was $12.3 million, slightly higher than the net loss of $12.1 million in Q4 2024, with total stock compensation expense increasing to $1.6 million from $0.8 million in the same period [5] - As of December 31, 2025, cash equivalents and marketable securities totaled $56.8 million, up from $52 million at the end of 2024, with pro forma cash including net proceeds from a public offering amounting to approximately $246 million, extending the cash runway into Q2 2028 [6] Business Line Data and Key Metrics Changes - Significant progress was made in the development of soquelitinib, with ongoing enrollment in the phase 3 trial for peripheral T-cell lymphoma (PTCL) and a recently initiated phase 2 trial for atopic dermatitis [9] - The phase 1 trial results for soquelitinib in atopic dermatitis showed a mean percent reduction in EASI of 72% compared to 40% for placebo, with 75% of patients achieving EASI 75 [12] Market Data and Key Metrics Changes - The company is entering 2026 with strong investor interest, highlighted by a $200 million financing, reflecting confidence in the potential of soquelitinib and ITK inhibition [8] - The phase 1 trial data presented at the ASH annual meeting indicated that soquelitinib could be a leading therapy for atopic dermatitis and other inflammatory diseases, with a favorable comparison to existing treatments [25] Company Strategy and Development Direction - The company plans to expand its clinical trials for soquelitinib into mid-stage trials for other inflammatory diseases such as hidradenitis suppurativa and asthma later in the year [9] - The strategy focuses on leveraging the unique mechanism of action of soquelitinib to address multiple inflammatory diseases, with ongoing research into its safety and efficacy [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term potential of soquelitinib across various indications, emphasizing the drug's unique properties and the promising clinical data supporting its use [27] - The company is optimistic about the upcoming data readouts from ongoing trials, which are expected to provide further insights into the drug's efficacy and safety [33] Other Important Information - The company is collaborating with Angel Pharmaceuticals for a phase 1b/2 trial in China, which is expected to provide additional data on soquelitinib's efficacy in atopic dermatitis [21] - The phase 2 trial for atopic dermatitis is set to enroll 200 patients, with results anticipated in mid-2027 [24] Q&A Session Summary Question: Regarding the upcoming data readouts for PTCL and the China study - Management indicated that initial data from Angel Pharmaceuticals' trial will be available later this year, with further data expected in 2027 [31][33] Question: Expectations for the SID meeting presentation - Management highlighted that the presentation will focus on durability and new biomarkers related to soquelitinib's mechanism of action [37] Question: Insights on the phase 2 trial in hidradenitis suppurativa - Management stated that they expect efficacy to be comparable or better than existing biologics, with ongoing assessments to determine optimal dosing [40] Question: Comments on the ALPS trial and its implications - Management noted that while results from the ALPS trial are promising, they do not directly predict outcomes for other autoimmune diseases [68] Question: Enrollment dynamics in the PTCL trial - Management confirmed that the trial is progressing well, with patients being randomized to receive either soquelitinib or standard care options [72][75] Question: Durability of response in the phase 2 trial - Management confirmed that the phase 2 trial includes a follow-up period to assess durability, although the primary endpoint remains the EASI score at 12 weeks [93]

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $82.4 million, a decrease of 1.3% year-over-year, but an improvement from the double-digit decline in Q3 [9][21] - Consumables revenue increased to $57.7 million from $56.7 million, representing a growth of 1.7% year-over-year [9] - Device revenue was $24.7 million, down 7.9% year-over-year, but showed improvement compared to Q3 [9] - Adjusted gross margin expanded to 67.4%, while GAAP gross margin increased to 64.4% [10][22] - Adjusted EBITDA for Q4 was $15 million, up from $9 million in the prior year, indicating a margin expansion of approximately 700 basis points [10][23] - For the full year, net sales were $300.8 million, down from $334.3 million in 2024, with consumables revenue totaling $212.7 million and device revenue at $88.1 million [20] Business Line Data and Key Metrics Changes - The company placed over 1,000 devices in Q4, ending the year with over 36,000 systems in its global install base [11] - The installed base is viewed as underutilized, with potential for significant consumables revenue growth through improved utilization [11] Market Data and Key Metrics Changes - The U.S. med spa market has grown from approximately 1,600 locations in 2010 to over 13,000 today, indicating a significant market expansion [6] - Consumer demographics are evolving, with increased engagement from men, Gen Z, and younger consumers seeking skin health treatments [6][7] Company Strategy and Development Direction - The company aims to shift its model from device placement to device utilization, focusing on unlocking the economic potential of its installed base [8] - Key strategic priorities include salesforce excellence, marketing discipline, and focused innovation [12][14] - The company plans to enhance its product ecosystem and strengthen its market position through disciplined innovation and targeted marketing efforts [15][16] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the aesthetic category, noting that demand for non-invasive treatments continues to grow globally [11] - The first half of 2026 is expected to be modestly below the prior year, with a stronger trajectory anticipated in the second half as execution initiatives take hold [17][24] - The company expects to return to growth in 2027, driven by operational changes and innovation [17][26] Other Important Information - The company ended 2025 with approximately $232.7 million in cash equivalents, a decrease from $370.1 million in 2024, primarily due to debt restructuring [21] - The company is focusing on improving its balance sheet and financial discipline, which has contributed to its stabilization [10][18] Q&A Session Summary Question: Guidance for 2026 and sales organization overhaul - Management expects revenue to be flat year-on-year, with Adjusted EBITDA slightly below 2025 due to reinvestment in R&D for future innovation [30][31] Question: Underlying market environment assumptions - Consumer spending remains selective, with a focus on clinically proven results at accessible price points, impacting procedure volume and device placements [36][37] Question: Churn trends and marketing to new demographics - Churn improved in Q4 to about 1.1%, with a focus on restructuring sales and customer service teams to better support smaller accounts [41][43] - The company is addressing the needs of new demographics, including men and Gen Z, by positioning HydraFacial as a lifestyle routine [45][46] Question: New system launch timeline and additional services - The next-generation HydraFacial is in early development, with a planned launch in 2028, aimed at providing compelling reasons for upgrades [51][52] Question: Consumables performance and pricing strategy - The company successfully implemented a 5% price increase on consumables without significant pushback, and is evaluating overall pricing strategy moving forward [74]

Financial Data and Key Metrics Changes - In 2025, Nephros reported total revenue of $18.8 million, a 33% increase from $14.2 million in 2024, driven by higher programmatic revenue and growth in active customer sites [9][10] - The net income for 2025 was approximately $1.2 million, compared to $0.1 million in 2024, marking the second consecutive year of profitability [13][14] - Gross margin for the fourth quarter of 2025 was 58%, down from 64% in the fourth quarter of 2024, primarily due to tariff impacts [11] Business Line Data and Key Metrics Changes - Active customer sites grew to over 1,680 by the end of 2025, up from just over 1,500 at the end of 2024, reflecting strong customer retention and outreach efforts [10][20] - Programmatic sales accounted for over 90% of total revenues in both the fourth quarter and the full year of 2025 [23][26] Market Data and Key Metrics Changes - The company is expanding into non-patient care applications, targeting markets such as hospitality, food services, and residential sectors, which are increasingly recognizing the importance of water safety [4][5] - The education initiative has reached over 1,000 participants through webinars and training sessions, establishing Nephros as a trusted authority in water safety [8][42] Company Strategy and Development Direction - Nephros' strategy is anchored around three core pillars: products, services, and education, which are driving growth and positioning the company as a leader in water safety solutions [5][9] - The company aims to penetrate new markets through key relationships and a focus on education to raise awareness about waterborne pathogen risks [4][29] Management's Comments on Operating Environment and Future Outlook - Management highlighted the increasing awareness of waterborne pathogens and rising regulatory expectations as key trends that position Nephros for growth [9][10] - The company anticipates that building markets outside of healthcare will take time, similar to the growth experienced in the hospital sector [32][29] Other Important Information - Nephros remains debt-free with approximately $5.4 million in cash at year-end 2025, reflecting financial discipline [9][16] - The company has faced tariff impacts, with a 15% tariff on goods imported from Italy, which was reduced to 10% in early 2026, creating uncertainty around future margins [11][12] Q&A Session Summary Question: What percentage of revenues for the fourth quarter and the full year were programmatic sales? - Programmatic sales accounted for over 90% of total revenues in both the fourth quarter and the full year of 2025 [23][26] Question: Can you discuss the pipeline potential outside of medical in the commercial space? - The company is focusing on educating different markets about the importance of water safety, which is crucial for growth in non-medical applications [28][29] Question: Can you elaborate on some successes in newer markets? - Nephros has seen successes in correctional facilities, schools, and aviation facilities, where there is a need for effective water filtration solutions [39][41]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $10.9 million, marking a 23% year-over-year growth, and full-year revenue reached $41.1 million, a 22% increase from $33.6 million in 2024 [20][22] - The company achieved positive cash flow from operations for both Q3 and Q4, and for the full year, with cash ending at $8.9 million [10][24] - Gross margin for the full year was 62.3%, with a slight reduction due to higher material costs and tariffs [23] Business Line Data and Key Metrics Changes - Domestic core business grew 18% year-over-year in Q4, while international core business saw an impressive growth of 71% [20][22] - The PST business decreased by 30% year-over-year due to milestone-based revenue recognition timing [21] - The recurring global patient base increased by approximately 20% to 59,000 patients [12] Market Data and Key Metrics Changes - The SCIG market grew approximately 10% in 2025, with KORU's domestic and international core businesses outperforming this growth [8][20] - In Europe, KORU's market share in the SCIG pump and consumables market increased from 10% in 2024 to 20% in 2025 [15] - The overall European SCIG market is valued at approximately $50 million, with significant growth potential as the market shifts from vial-based delivery to prefilled syringes [15][16] Company Strategy and Development Direction - KORU is focused on three strategic pillars: protecting and growing the core domestic business, expanding internationally, and enabling more drugs to reach more patients [10][31] - The company aims to diversify its business with new product developments and collaborations, including entry into oncology and nephrology markets [12][13] - KORU plans to leverage its strong position in the SCIG market, which is projected to grow at 8%-10% over the next five years [11][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, with 2026 revenue guidance set at $47.5 million to $50 million, representing a growth of 15%-22% [10][25] - The company is prepared for geopolitical risks and anticipates a ramp-up in revenue in the second half of 2026 as new products are introduced [26] - Management highlighted the importance of operational excellence programs to offset external cost pressures [27] Other Important Information - The CEO announced retirement effective June 30, 2026, with the Chief Commercial Officer set to succeed [4][5] - KORU received EU MDR certification for the Freedom60 system, enabling prefilled syringe compatibility, which is expected to enhance market penetration [9][29] Q&A Session Summary Question: What does the Freedom60 product do for the market? - The Freedom60 opens up a $50 million total addressable market in Europe, with significant share gain potential as the company moves from 10% to 20% market share [35] Question: Can you provide more detail on the guidance range? - The guidance range is influenced by the speed of prefill conversions and new drug approvals, with potential impacts from geopolitical factors [66] Question: What is the growth opportunity in Japan? - Japan is seen as a significant market with potential for half a million to a million-dollar opportunity as the market shifts towards home care [70]

Financial Data and Key Metrics Changes - As of December 31, 2025, cash equivalents and marketable securities totaled approximately $318.1 million, up from approximately $151.5 million as of December 31, 2024 [24] - Revenue for Q4 2025 was $0, compared to approximately $11.1 million for Q4 2024, and for the full year 2025, revenue was also $0, down from approximately $22.3 million in 2024 [24] - Total operating expenses for Q4 2025 were approximately $29.2 million, compared to approximately $18.8 million for Q4 2024, with full-year operating expenses at approximately $108.1 million, up from approximately $64.8 million in 2024 [25] - Net loss for Q4 2025 was approximately $30.2 million, compared to a net loss of approximately $7.1 million for Q4 2024, and for the full year 2025, the net loss was approximately $105 million, compared to approximately $40.5 million in 2024 [26] Business Line Data and Key Metrics Changes - The company is focused on advancing Deramiocel for Duchenne muscular dystrophy (DMD), with a Biologics License Application (BLA) under review by the FDA [4][5] - The HOPE-3 trial showed significant results, including a 91% slowing of disease progression in left ventricular ejection fraction among evaluable patients [7][8] - The company aims to position Deramiocel to treat as many eligible patients as possible, with a focus on both skeletal and cardiac disease manifestations of DMD [5][6] Market Data and Key Metrics Changes - The FDA has accepted the BLA for review with a target action date of August 22, 2026, marking a significant regulatory milestone for the company [4][15] - The company is preparing for a potential commercial launch and has completed its FDA pre-license inspection for its manufacturing facility [16][17] Company Strategy and Development Direction - The company is building an infrastructure to support the launch and commercialization of Deramiocel while expanding its pipeline to treat other indications [6][19] - The company is also exploring expansion into other diseases, initially focusing on Becker muscular dystrophy [19] - The company is committed to maintaining a disciplined approach to execution and investing in its pipeline to operate as a world-class commercial biotech company [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the data and the company's manufacturing readiness, positioning it well for growth [6][15] - The company is focused on addressing the unmet needs of the DMD community and is preparing for a potential commercial launch [17][18] - Management highlighted the importance of the HOPE-3 trial data in supporting the therapeutic profile of Deramiocel [14][15] Other Important Information - The company ended 2025 with a strong cash position of approximately $318 million, which is expected to fund operations into the fourth quarter of 2027 [22] - The company has been approved for uplisting to the Nasdaq Global Select Market, enhancing visibility within the institutional investment community [23] Q&A Session Summary Question: Anticipation of Ad Com and commercial preparation for Deramiocel approval - Management indicated that there has been no movement towards an Advisory Committee meeting and expressed confidence in the strength of the HOPE-3 data regardless of the review process [30][32] Question: Clarification on the label for Deramiocel - Management believes the data supports a label for both DMD and cardiomyopathy, with ongoing discussions with the FDA [34][35] Question: Status of the two cohorts in the HOPE-3 trial - Management confirmed that the FDA considers the two cohorts as one trial and expressed confidence in the statistical significance of cohort B [39][41] Question: Expectations for the peer-reviewed publication of HOPE-3 data - Management stated that the academic review process is ongoing and updates will be provided once the publication is ready [42] Question: Insights from the Muscular Dystrophy Association meeting - Management noted that the HOPE-3 data has solidified belief in Deramiocel among physicians and increased inquiries about prescribing and availability [60] Question: Plans for scaling manufacturing capacity - Management confirmed plans for additional manufacturing build-out to accommodate more patients, contingent on the successful response to the BLA [66][67]

Financial Data and Key Metrics Changes - Inovio reported a net income of $3.8 million or $0.06 per share for Q4 2025, compared to a net loss of $84.9 million or $1.81 per share for the full year 2025 [25][26] - Total operating expenses decreased from $20.5 million in Q4 2024 to $17.5 million in Q4 2025, and full-year operational expenses dropped 23% from $112.6 million in 2024 to $86.9 million in 2025 [25][26] - Cash equivalents and short-term investments decreased to $58.5 million as of December 31, 2025, down from $94.1 million a year earlier [25] Business Line Data and Key Metrics Changes - The primary focus remains on advancing INO-3107 towards FDA approval, with significant resources allocated to this lead candidate [5][24] - The company is also advancing other promising candidates in its pipeline, including INO-5412 for glioblastoma, through partnerships [8][21] Market Data and Key Metrics Changes - The FDA accepted the BLA for INO-3107 under the Accelerated Approval Program, with a PDUFA target date set for October 30, 2026 [5][6] - Market research indicates strong physician interest in INO-3107 due to its efficacy and tolerability, with a significant reduction in surgeries for patients [16][35] Company Strategy and Development Direction - The company is focused on optimizing resources to extend its cash runway towards the October PDUFA date while advancing its pipeline [24][58] - Inovio aims to leverage partnerships to enhance its research capabilities and expedite the development of its DNA medicines platform [8][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in INO-3107's ability to meet an unmet medical need and provide a meaningful therapeutic benefit over existing treatments [5][11] - The company is preparing for discussions with the FDA regarding the accelerated approval and is optimistic about the potential for INO-3107 to become a preferred treatment option [29][35] Other Important Information - The company has reduced headcount by approximately 15% to conserve financial resources and extend its cash runway [24] - The recent market research supports the belief that INO-3107 could become the preferred treatment based on its efficacy and simple treatment regimen [16][35] Q&A Session Summary Question: What additional data is needed for FDA conversations regarding accelerated approval? - No new clinical data is required, but new documentation has been submitted to the FDA [28][29] Question: How would a six-month priority review timeline impact launch preparations? - The focus is currently on ensuring alignment with the FDA for accelerated approval, with commercial preparations well advanced [32][33] Question: What feedback was received from KOLs and patients regarding recent publications? - Research indicates a strong preference for INO-3107 due to its efficacy and tolerability, with significant reductions in surgeries reported [35][36] Question: How is the company using learnings from competitors for launch strategy? - The company is observing competitor strategies and leveraging the experience of its commercial partners to prepare for launch [41][43] Question: Can you explain the rationale behind the Akeso partnership? - The partnership aims to enhance immune responses against tumor-associated antigens through a dual PD-1/CTLA-4 blockade [46][47]

Financial Data and Key Metrics Changes - For Q4 2025, total revenues were $2.2 million, a 76% increase from $1.3 million in Q4 2024, primarily due to higher unit sales of M400 smart glasses and increased engineering services sales [20] - For the full year 2025, total revenues were $6.3 million, up 9% from $5.8 million in 2024 [21] - The overall gross loss for 2025 was $1.1 million, significantly improved from a loss of $5.6 million in 2024, mainly due to lower inventory obsolescence reserves [22] - The net loss attributable to common shareholders for Q4 2025 was $8.7 million or $0.12 per share, compared to a net loss of $13.7 million or $0.16 per share in Q4 2024 [26] - For the full year 2025, the net loss was $32.3 million or $0.42 per share, down from $73.5 million or $1.08 per share in 2024 [27] Business Line Data and Key Metrics Changes - Product sales increased by 4% year-over-year, driven by greater unit sales of M400 products [22] - Engineering services sales for 2025 were $1.6 million, up 27% from $1.3 million in 2024 [22] - Research and development expenses rose 31% to $12.6 million in 2025, primarily due to increased external development costs for the new LX1 smart glasses [23] Market Data and Key Metrics Changes - The enterprise markets are becoming more mature and ROI-driven, with customers focused on solutions that improve workflow efficiency and enhance safety [17] - The defense and security agencies segment is seeing growth in active programs and discussions, with a mix of activities including active deliveries and contracted programs [12] Company Strategy and Development Direction - The company is focusing on its OEM products and waveguide technology as key growth engines, with a strategic shift towards more selective investment in branded products [6][9] - The long-term growth strategy is centered around engineering services, with an emphasis on partnerships and customized solutions for large-scale enterprises [8] - The company aims to leverage its waveguide technology for scalable production, positioning itself in the next generation of AI and AR-enabled smart glasses [8][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth of the OEM business and waveguide technology, expecting revenues from these areas to surpass those from the branded enterprise side by the end of 2026 [33] - The company anticipates multiple new business partnerships and orders throughout 2026, indicating a strong pipeline of opportunities [35] - Management highlighted the importance of strategic relationships and the value created through improved business structure and operational capabilities [41] Other Important Information - The company ended 2025 with a cash position of $21.2 million, an increase from $18.2 million in 2024, and no current or long-term debt [27][28] - Inventory levels improved, with net inventory declining to $2.2 million as of December 31, 2025, compared to $4.8 million at the end of 2024 [28] Q&A Session Summary Question: Expectations for 2026 revenue and significant revenue sources - Management expects the OEM and waveguide business to grow quarter after quarter, potentially surpassing revenues from the branded enterprise side by year-end [33] Question: Anticipation of additional orders and announcements in 2026 - Management indicated that there would likely be several announcements regarding orders and partnerships throughout 2026, contributing to new business opportunities [35]

Financial Data and Key Metrics Changes - In Q4 2025, net sales decreased by 20.6% to $87.7 million compared to $110.5 million in Q4 2024 [13] - Full-year net sales were down 6.7%, totaling $368.3 million in 2025 versus $394.9 million in 2024 [13] - Adjusted non-GAAP profit for Q4 2025 was $26.1 million, or 29.7% of sales, up from 28.4% in Q4 2024 [15] - Full-year adjusted non-GAAP net income was $4.2 million, or $0.31 per share, compared to a loss of $0.6 million, or $0.05 per share in 2024 [19] Business Line Data and Key Metrics Changes - Connected Home sales increased by $17.1 million, or 15.8%, to $125.4 million for the full year, driven by new orders in climate control and HVAC [14] - Home entertainment sales decreased by $43.7 million, or 15.2%, to $242.9 million for the full year [15] - Q4 2025 home entertainment sales were down 23.8% to $58 million, reflecting lower demand for subscription broadcasting products [15] Market Data and Key Metrics Changes - The company noted a slowdown in the connected home market, which began in the second half of 2025, due to industry consolidation and economic pressures in Europe [8] - Customer forecasts and orders indicated that revenue inflection in the connected home segment would take longer than expected [9] Company Strategy and Development Direction - The company is focused on restructuring to align with the revenue and margin profile expected for 2026, including a reduction in force and cost reductions across various areas [10] - The strategy includes optimizing R&D and portfolio focus on high-revenue and margin opportunities [10] - The company aims to improve operational efficiency, strengthen profitability, and generate more free cash flow as part of its long-term strategy [22] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges in the home entertainment business and the slower-than-expected growth in the connected home segment [6] - The company is adopting a conservative outlook for 2026, expecting a decline in revenue due to market headwinds [20] - Management emphasized the importance of maintaining operational discipline and focusing on profitability amid ongoing economic uncertainties [8] Other Important Information - The company achieved a positive net cash position for the first time since 2021, with a net cash balance of $8.2 million [19] - Significant cost-saving measures were implemented, including reducing manufacturing footprint and overhead, which contributed to improved operating leverage [16] Q&A Session Summary Question: Guidance on revenue decline for 2026 - Management could not provide specific decline percentages but emphasized a focus on improving cash flow and profits [24] Question: Details on expense reductions - Management indicated that operating expenses would be significantly reduced in alignment with revenue adjustments [25] Question: Size of the reduction in force (RIF) in Q4 - The RIF in Q4 involved approximately 50 employees [26] Question: Major customers in Q4 - Major customers included Daikin at close to 16% and Comcast at close to 11% of sales [30] Question: Licensing revenue sources - Licensing revenue in Q4 was primarily from the traditional home entertainment business, with plans to expand in the connected home segment [31]